Additionally, proteomic analysis in breast cancer patients has highlighted a strong positive correlation between PAD2 expression and a B-cell immune signature, as well as with MHC class II-bound citrullinated peptides [206]. This evidence concerns the gene PADI2 and breast carcinoma.